MURALI CHINTAGUMPALA to Biomarkers, Tumor
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Biomarkers, Tumor.
Connection Strength
1.045
-
Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013 Jul 15; 119(14):2630-8.
Score: 0.247
-
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 05 15; 27(10):2879-2889.
Score: 0.107
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
Score: 0.106
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
Score: 0.105
-
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
Score: 0.088
-
Neuroendocrine Tumor of the Appendix in Children. J Pediatr Hematol Oncol. 2017 03; 39(2):97-102.
Score: 0.081
-
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
Score: 0.078
-
Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol. 2008 Jan; 86(2):183-90.
Score: 0.042
-
Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics. 2006 Jun; 6(11):3426-35.
Score: 0.038
-
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004 Mar 15; 22(6):984-93.
Score: 0.033
-
Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study. Pediatr Hematol Oncol. 2023; 40(8):719-738.
Score: 0.031
-
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021 11 08; 39(11):1519-1530.e4.
Score: 0.028
-
Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma. J Neurooncol. 2016 05; 128(1):47-56.
Score: 0.019
-
Therapeutic implications of CD1d expression and tumor-infiltrating macrophages in pediatric medulloblastomas. J Neurooncol. 2014 Nov; 120(2):293-301.
Score: 0.017
-
Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep. 2011 Feb; 25(2):303-14.
Score: 0.013
-
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer. 2011 Jan 01; 117(1):207-17.
Score: 0.013